Chronic Obstructive Pulmonary Disease-Pipeline Review, H1 2017

Chronic Obstructive Pulmonary Disease-Pipeline Review, H1 2017


  • Products Id :- GMDHC9293IDB
  • |
  • Pages: 466
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Chronic Obstructive Pulmonary Disease-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Obstructive Pulmonary Disease-Pipeline Review, H1 2017, provides an overview of the Chronic Obstructive Pulmonary Disease (Respiratory) pipeline landscape.

Chronic obstructive pulmonary disease (COPD) is a group of lung diseases. It is characterized by inability to completely breathe out air from the lungs leading to shortness of breath. The airflow to the lungs is further blocked. Other symptoms include cough, fatigue and chest pain. The disease tends to worsen over the time hence increasing the complications. The risk factors involved in causing COPD include smoking as the primary reason. Exposure to chemicals and air pollution also contribute in the development of COPD.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Obstructive Pulmonary Disease-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chronic Obstructive Pulmonary Disease (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Obstructive Pulmonary Disease (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 5, 1, 14, 38, 23, 85, 25 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 9 and 1 molecules, respectively.

Chronic Obstructive Pulmonary Disease (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Obstructive Pulmonary Disease (Respiratory).

The pipeline guide reviews pipeline therapeutics for Chronic Obstructive Pulmonary Disease (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Chronic Obstructive Pulmonary Disease (Respiratory) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Chronic Obstructive Pulmonary Disease (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Obstructive Pulmonary Disease (Respiratory)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Chronic Obstructive Pulmonary Disease (Respiratory).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Chronic Obstructive Pulmonary Disease (Respiratory) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

Introduction 7

Chronic Obstructive Pulmonary Disease (COPD)-Overview 8

Chronic Obstructive Pulmonary Disease (COPD)-Therapeutics Development 9

Chronic Obstructive Pulmonary Disease (COPD)-Therapeutics Assessment 32

Chronic Obstructive Pulmonary Disease (COPD)-Companies Involved in Therapeutics Development 48

Chronic Obstructive Pulmonary Disease (COPD)-Drug Profiles 97

Chronic Obstructive Pulmonary Disease (COPD)-Dormant Projects 416

Chronic Obstructive Pulmonary Disease (COPD)-Discontinued Products 430

Chronic Obstructive Pulmonary Disease (COPD)-Product Development Milestones 434

Appendix 445

List of Figures

Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Top 10 Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

List of Tables

Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Products under Development by Companies, H1 2017 (Contd..7), H1 2017

Products under Development by Companies, H1 2017 (Contd..8), H1 2017

Products under Development by Companies, H1 2017 (Contd..9), H1 2017

Products under Development by Companies, H1 2017 (Contd..10), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Abeona Therapeutics Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Achillion Pharmaceuticals Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Adamis Pharmaceuticals Corp, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Advanced Inhalation Therapies (AIT) Ltd, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Advinus Therapeutics Ltd, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by AlgiPharma AS, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Allinky Biopharma, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Alteogen Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Amakem NV, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Angiocrine Bioscience Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Angion Biomedica Corp, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by apceth Biopharma GmbH, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Apellis Pharmaceuticals Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Aridis Pharmaceuticals LLC, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Astellas Pharma Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by AstraZeneca Plc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Asubio Pharma Co Ltd, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Axikin Pharmaceuticals Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Bayer AG, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Beech Tree Labs Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Bioneer Corp, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Boehringer Ingelheim GmbH, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by C4X Discovery Holdings PLC, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Carolus Therapeutics Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Cellular Biomedicine Group Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Celon Pharma SA, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Chiesi Farmaceutici SpA, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Circassia Pharmaceuticals Plc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by CSL Ltd, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Cytokinetics Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Daiichi Sankyo Company Ltd, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Diffusion Pharmaceuticals Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Domainex Ltd, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Enterprise Therapeutics Ltd, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Errant Gene Therapeutics LLC, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Foresee Pharmaceuticals LLC, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Galapagos NV, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Gilead Sciences Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by GlaxoSmithKline Plc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Glenmark Pharmaceuticals Ltd, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Grifols SA, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by iCeutica Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by InMed Pharmaceuticals Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Innate Pharma SA, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Insmed Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Intech Biopharm Ltd, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Invion Ltd, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Johnson & Johnson, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by KaloBios Pharmaceuticals Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Kissei Pharmaceutical Co Ltd, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Medestea Research & Production SpA, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by MedImmune LLC, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Mereo Biopharma Group Plc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Meridigen Biotech Co Ltd, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Microbion Corp, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Novartis AG, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Odan Laboratories Ltd, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by OPKO Health Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Orchid Pharma Ltd, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Orion Oyj, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Pfizer Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Pharmaxis Ltd, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Promedior Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by ProMetic Life Sciences Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Proteostasis Therapeutics Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Pulmagen Therapeutics LLP, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Pulmatrix Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Qu Biologics Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Quark Pharmaceuticals Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Re-Pharm Ltd, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Regeneron Pharmaceuticals Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Respira Therapeutics Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Respiratorius AB, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by rEVO Biologics Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Rhizen Pharmaceuticals SA, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by SATT North SAS, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Seoul Pharma Co Ltd, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by sterna biologicals Gmbh & Co KG, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Sunovion Pharmaceuticals Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Synedgen Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Syntrix Biosystems Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Teva Pharmaceutical Industries Ltd, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Therabron Therapeutics Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Theravance Biopharma Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Torrent Pharmaceuticals Ltd, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Unizyme Laboratories A/S, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Vectura Group Plc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Verona Pharma Plc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Vertex Pharmaceuticals Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Yuhan Corp, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Yungjin Pharm Co Ltd, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Dormant Projects, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Dormant Projects, H1 2017 (Contd..1), H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Dormant Projects, H1 2017 (Contd..2), H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Dormant Projects, H1 2017 (Contd..3), H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Dormant Projects, H1 2017 (Contd..4), H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Dormant Projects, H1 2017 (Contd..5), H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Dormant Projects, H1 2017 (Contd..6), H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Dormant Projects, H1 2017 (Contd..7), H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Dormant Projects, H1 2017 (Contd..8), H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Dormant Projects, H1 2017 (Contd..9), H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Dormant Projects, H1 2017 (Contd..10), H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Dormant Projects, H1 2017 (Contd..11), H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Dormant Projects, H1 2017 (Contd..12), H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Dormant Projects, H1 2017 (Contd..13), H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Discontinued Products, H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Discontinued Products, H1 2017 (Contd..1), H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Discontinued Products, H1 2017 (Contd..2), H1 2017

Chronic Obstructive Pulmonary Disease (COPD)-Discontinued Products, H1 2017 (Contd..3), H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Abeona Therapeutics Inc, Achillion Pharmaceuticals Inc, Adamis Pharmaceuticals Corp, Advanced Inhalation Therapies (AIT) Ltd, Advinus Therapeutics Ltd, AlgiPharma AS, Allinky Biopharma, Alteogen Inc, Amakem NV, Angiocrine Bioscience Inc, Angion Biomedica Corp, apceth Biopharma GmbH, Apellis Pharmaceuticals Inc, Aridis Pharmaceuticals LLC, Astellas Pharma Inc, AstraZeneca Plc, Asubio Pharma Co Ltd, Axikin Pharmaceuticals Inc, Bayer AG, Beech Tree Labs Inc, Bioneer Corp, Boehringer Ingelheim GmbH, C4X Discovery Holdings PLC, Carolus Therapeutics Inc, Cellular Biomedicine Group Inc, Celon Pharma SA, Chiesi Farmaceutici SpA, Circassia Pharmaceuticals Plc, CSL Ltd, Cytokinetics Inc, Daiichi Sankyo Company Ltd, Diffusion Pharmaceuticals Inc, Domainex Ltd, Enterprise Therapeutics Ltd, Errant Gene Therapeutics LLC, F. Hoffmann-La Roche Ltd, Foresee Pharmaceuticals LLC, Galapagos NV, Gilead Sciences Inc, GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd, Grifols SA, Hanmi Pharmaceuticals Co Ltd, iCeutica Inc, InMed Pharmaceuticals Inc, Innate Pharma SA, Insmed Inc, Intech Biopharm Ltd, Invion Ltd, Jiangsu Hansoh Pharmaceutical Group Co Ltd, Johnson & Johnson, KaloBios Pharmaceuticals Inc, Kissei Pharmaceutical Co Ltd, Kyowa Hakko Kirin Co Ltd, Medestea Research & Production SpA, MedImmune LLC, Mereo Biopharma Group Plc, Meridigen Biotech Co Ltd, Microbion Corp, Novartis AG, Odan Laboratories Ltd, OPKO Health Inc, Orchid Pharma Ltd, Orion Oyj, Pfizer Inc, Pharmaxis Ltd, Promedior Inc, ProMetic Life Sciences Inc, Proteostasis Therapeutics Inc, Pulmagen Therapeutics LLP, Pulmatrix Inc, Qu Biologics Inc, Quark Pharmaceuticals Inc, Re-Pharm Ltd, Regeneron Pharmaceuticals Inc, Respira Therapeutics Inc, Respiratorius AB, rEVO Biologics Inc, Rhizen Pharmaceuticals SA, SATT North SAS, Seoul Pharma Co Ltd, sterna biologicals Gmbh & Co KG, Sun Pharma Advanced Research Company Ltd, Sunovion Pharmaceuticals Inc, Synedgen Inc, Syntrix Biosystems Inc, Takeda Pharmaceutical Company Ltd, Teva Pharmaceutical Industries Ltd, Therabron Therapeutics Inc, Theravance Biopharma Inc, Torrent Pharmaceuticals Ltd, Unizyme Laboratories A/S, Vectura Group Plc, Verona Pharma Plc, Vertex Pharmaceuticals Inc, Yuhan Corp, Yungjin Pharm Co Ltd

Chronic Obstructive Pulmonary Disease (COPD) Therapeutic Products under Development, Key Players in Chronic Obstructive Pulmonary Disease (COPD) Therapeutics, Chronic Obstructive Pulmonary Disease (COPD) Pipeline Overview, Chronic Obstructive Pulmonary Disease (COPD) Pipeline, Chronic Obstructive Pulmonary Disease (COPD) Pipeline Assessment

select a license
Single User License
USD 2000 INR 143800
Site License
USD 4000 INR 287600
Corporate User License
USD 6000 INR 431400

NEWSLETTER BY CATEGORY




Testimonials

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com